<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34635304</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1558-3163</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Rheumatic diseases clinics of North America</Title>
          <ISOAbbreviation>Rheum Dis Clin North Am</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Recent Advances in Pediatric Vasculitis.</ArticleTitle>
        <Pagination>
          <StartPage>781</StartPage>
          <EndPage>796</EndPage>
          <MedlinePgn>781-796</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rdc.2021.07.007</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0889-857X(21)01101-7</ELocationID>
        <Abstract>
          <AbstractText>This article provides an overview of the clinical presentation and diagnosis of select pediatric primary systemic vasculitides. Important advances in understanding the pathogenesis of these rare diseases also are discussed and efforts to harmonize treatment through consensus-based guidelines and multicenter and international collaborations highlighted.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cannon</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Rheumatology, Department of Pediatrics, Duke University, 2301 Erwin Road, DUMC Box 3212, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Eveline Y</ForeName>
            <Initials>EY</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Rheumatology, Department of Pediatrics, The University of North Carolina Chapel Hill, 030 MacNider Hall, CB #7231, Chapel Hill, NC 27599, USA; Division of Allergy/Immunology, Department of Pediatrics, The University of North Carolina Chapel Hill, Chapel Hill, NC. Electronic address: eveline.wu@unc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>KL2 TR002490</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Rheum Dis Clin North Am</MedlineTA>
        <NlmUniqueID>8708093</NlmUniqueID>
        <ISSNLinking>0889-857X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014657" MajorTopicYN="Y">Vasculitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Childhood</Keyword>
        <Keyword MajorTopicYN="Y">Pediatric</Keyword>
        <Keyword MajorTopicYN="Y">Systemic</Keyword>
        <Keyword MajorTopicYN="Y">Vasculitides</Keyword>
        <Keyword MajorTopicYN="Y">Vasculitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34635304</ArticleId>
        <ArticleId IdType="mid">NIHMS1727262</ArticleId>
        <ArticleId IdType="pmc">PMC9083080</ArticleId>
        <ArticleId IdType="doi">10.1016/j.rdc.2021.07.007</ArticleId>
        <ArticleId IdType="pii">S0889-857X(21)01101-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jennette JC, Falk RJ, Bacon PA, et al.
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum
2013; 65(1):1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23045170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sag E, Batu ED, Ozen S. Childhood systemic vasculitis. Best Pract Res Clin Rheumatol
2017;31(4):558–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29773273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunner J, Feldman BM, Tyrrell PN, et al.
Takayasu arteritis in children and adolescents. Rheumatology
2010;49(10):1806–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20562196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cakar N, Yalcinkaya F, Duzova A, et al.
Takayasu arteritis in children. J Rheumatol
2008;35(5):913–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18381778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Souza AW, de Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis. J Autoimmun
2014;48–49:79–83.</Citation>
        </Reference>
        <Reference>
          <Citation>Batu ED, Sonmez HE, Hazirolan T, et al.
Tocilizumab treatment in childhood Takayasu arteritis: case series of four patients and systematic review of the literature. Semin Arthritis Rheum
2017;46(4):529–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27515155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahin S, Hopurcuoglu D, Bektas S, et al.
Childhood-onset Takayasu arteritis: a 15-year experience from a tertiary referral center. Int J Rheum Dis
2019;22(1):132–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30397997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan L, Zhang H, Cai J, et al.
Clinical course and prognostic factors of childhood Takayasu’s arteritis: over 15-year comprehensive analysis of 101 patients. Arthritis Res Ther
2019;21(1):31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6341556</ArticleId>
            <ArticleId IdType="pubmed">30670069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Hughes M, Sebire N, et al.
Takayasu arteritis in infancy. Rheumatology
2013;52(11):2093–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23584240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aeschlimann FA, Eng SWM, Sheikh S, et al.
Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Res Ther
2017;19(1):255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5700506</ArticleId>
            <ArticleId IdType="pubmed">29166923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozen S, Pistorio A, Iusan SM, et al.
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis
2010;69(5):798–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20413568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruperto N, Ozen S, Pistorio A, et al.
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterisation. Ann Rheum Dis
2010;69(5):790–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20388738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozen S, Duzova A, Bakkaloglu A, et al.
Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr
2007;150(1):72–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17188618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szugye HS, Zeft AS, Spalding SJ. Takayasu Arteritis in the pediatric population: a contemporary United States-based single center cohort. Pediatr Rheumatol Online J
2014;12:21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4065084</ArticleId>
            <ArticleId IdType="pubmed">24955077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern S, Clemente G, Reiff A, et al.
Treatment of pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort study. J Clin Rheumatol
2014;20(4):183–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24847743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. Front Pediatr
2018;6:374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6298241</ArticleId>
            <ArticleId IdType="pubmed">30619784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makino N, Nakamura Y, Yashiro M, et al.
Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J Epidemiol
2015;25(3):239–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4341001</ArticleId>
            <ArticleId IdType="pubmed">25716368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rife E, Gedalia A. Kawasaki disease: an update. Curr Rheumatol Rep
2020; 22(10):75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7487199</ArticleId>
            <ArticleId IdType="pubmed">32924089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holman RC, Belay ED, Christensen KY, et al.
Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. Pediatr Infect Dis J
2010;29(6):483–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20104198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundel RP. Kawasaki disease. Rheum Dis Clin North Am
2015;41(1):63–73, viii.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25399940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCrindle BW, Rowley AH, Newburger JW, et al.
Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation
2017;135(17):e927–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28356445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wardle AJ, Connolly GM, Seager MJ, et al.
Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev
2017;1(1):Cd011188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6464937</ArticleId>
            <ArticleId IdType="pubmed">28129459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Son MBF, Gauvreau K, Kim S, et al.
Predicting coronary artery aneurysms in Kawasaki disease at a North American Center: an assessment of baseline z scores. J Am Heart Assoc
2017;6(6).</Citation>
        </Reference>
        <Reference>
          <Citation>Son MBF, Gauvreau K, Tremoulet AH, et al.
Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. J Am Heart Assoc
2019;8(11):e011319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6585355</ArticleId>
            <ArticleId IdType="pubmed">31130036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graeff N, Groot N, Ozen S, et al.
European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology
2019;58(4):672–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30535127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi T, Saji T, Otani T, et al.
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet
2012; 379(9826):1613–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22405251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Jain S, Jaggi P, et al.
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet
2014;383(9930):1731–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24572997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns JC, Best BM, Mejias A, et al.
Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr
2008;153(6):833–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2856847</ArticleId>
            <ArticleId IdType="pubmed">18672254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaji N, da Silva Lopes K, Shoda T, et al.
TNF-α blockers for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev
2019;8(8):Cd012448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6953355</ArticleId>
            <ArticleId IdType="pubmed">31425625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol
2010;25(9):1641–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2908435</ArticleId>
            <ArticleId IdType="pubmed">19946711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol
1996;23(11):1968–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8923377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozen S, Anton J, Arisoy N, et al.
Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr
2004;145(4):517–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15480378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eleftheriou D, Dillon MJ, Tullus K, et al.
Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum
2013; 65(9):2476–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23754739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caorsi R, Penco F, Grossi A, et al.
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis
2017;76(10):1648–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28522451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navon Elkan P, Pierce SB, Segel R, et al.
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med
2014;370(10):921–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24552285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozen S, Ben-Chetrit E, Bakkaloglu A, et al.
Polyarteritis nodosa in patients with Familial Mediterranean Fever (FMF): a concomitant disease or a feature of FMF?
Semin Arthritis Rheum
2001;30(4):281–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11182028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Jesus AA, Marrero B, et al.
Activated STING in a vascular and pulmonary syndrome. N Engl J Med
2014;371(6):507–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4174543</ArticleId>
            <ArticleId IdType="pubmed">25029335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozen S, Ruperto N, Dillon MJ, et al.
EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis
2006;65(7):936–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1798210</ArticleId>
            <ArticleId IdType="pubmed">16322081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brogan PA, Arch B, Hickey H, et al.
Mycophenolate mofetil versus cyclophosphamide for remission induction in childhood polyarteritis nodosa: an open label, randomised, Bayesian, non-inferiority trial. Arthritis Rheumatol March
24, 2021. 10.1002/art.41730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ginsberg S, Rosner I, Slobodin G, et al.
Infliximab for the treatment of refractory polyarteritis nodosa. Clin Rheumatol
2019;38(10):2825–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30972576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eleftheriou D, Melo M, Marks SD, et al.
Biologic therapy in primary systemic vasculitis of the young. Rheumatology
2009;48(8):978–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19535611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardner-Medwin JM, Dolezalova P, Cummins C, et al.
Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet
2002;360(9341):1197–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12401245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss PF, Feinstein JA, Luan X, et al.
Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics
2007;120(5):1079–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3525094</ArticleId>
            <ArticleId IdType="pubmed">17974746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine
1999;78(6):395–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10575422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Sheyyab M, El-Shanti H, Ajlouni S, et al.
The clinical spectrum of Henoch-Schönlein purpura in infants and young children. Eur J Pediatr
1995;154(12):969–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8801104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calviño MC, Llorca J, García-Porrúa C, et al.
Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine
2001;80(5):279–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11552081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss PF, Klink AJ, Luan X, et al.
Temporal association of Streptococcus, Staphylococcus, and parainfluenza pediatric hospitalizations and hospitalized cases of Henoch-Schönlein purpura. J Rheumatol
2010;37(12):2587–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20843903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farley TA, Gillespie S, Rasoulpour M, et al.
Epidemiology of a cluster of Henoch-Schönlein purpura. Am J Dis Child
1989;143(7):798–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2741850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber AM, King J, McLaine P, et al.
A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. BMC Med
2004;2:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC400510</ArticleId>
            <ArticleId IdType="pubmed">15059282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narchi H
Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child
2005;90(9):916–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1720564</ArticleId>
            <ArticleId IdType="pubmed">15871983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trygstad CW, Stiehm ER. Elevated serum IgA globulin in anaphylactoid purpura. Pediatrics
1971;47(6):1023–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5003905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronkainen J, Koskimies O, Ala-Houhala M, et al.
Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr
2006;149(2):241–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16887443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss PF, Klink AJ, Localio R, et al.
Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics
2010; 126(4):674–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3518383</ArticleId>
            <ArticleId IdType="pubmed">20855386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dudley J, Smith G, Llewelyn-Edwards A, et al.
Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). Arch Dis Child
2013;98(10):756–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23845696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chartapisak W, Opastiraku S, Willis NS, et al.
Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review. Arch Dis Child
2009;94(2):132–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18701559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozen S, Marks SD, Brogan P, et al.
European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology
2019;58(9):1607–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30879080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saulsbury FT. Henoch-Schönlein purpura. Curr Opin Rheumatol
2010;22(5): 598–602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20473173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacri AS, Chambaraud T, Ranchin B, et al.
Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transpl
2015;30(Suppl 1):i104–12.</Citation>
        </Reference>
        <Reference>
          <Citation>Jariwala MP, Laxer RM. Primary vasculitis in childhood: GPA and MPA in childhood. Front Pediatr
2018;6:226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6107029</ArticleId>
            <ArticleId IdType="pubmed">30167431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano D, Ishikawa T, Inaba A, et al.
Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: a clinicopathological analysis. Pediatr Nephrol
2019;34(8):1425–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31076873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabral DA, Canter DL, Muscal E, et al.
Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): An ARChiVe cohort study. Arthritis Rheumatol
2016;68(10):2514–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27111558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyons PA, Rayner TF, Trivedi S, et al.
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med
2012;367(3):214–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3773907</ArticleId>
            <ArticleId IdType="pubmed">22808956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol
2014;10(8):463–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25003769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu EY, McInnis EA, Boyer-Suavet S, et al.
Measuring circulating complement activation products in myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol
2019;71(11):1894–903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6817386</ArticleId>
            <ArticleId IdType="pubmed">31215772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu EY, Hernandez ML, Jennette JC, et al.
Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review. J Allergy Clin Immunol Pract
2018;6(5):1496–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30197069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uribe AG, Huber AM, Kim S, et al.
Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis. J Rheumatol
2012;39(8):1687–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22589257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iudici M, Pagnoux C, Quartier P, et al.
Childhood- versus adult-onset ANCA-associated vasculitides: a nested, matched case-control study from the French Vasculitis Study Group Registry. Autoimmun Rev
2018;17(2):108–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29180123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita KA, Moorthy LN, Lubieniecka JM, et al.
Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol
2017;69(7):1470–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28371513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolezalova P, Price-Kuehne FE,Özen S, et al.
Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis
2013;72(10):1628–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23100606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita KA, Wagner-Weiner L, Yen EY, et al.
Consensus treatment plans for severe pediatric antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res
March
6, 2021. 10.1002/acr.24590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.24590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JJY, Alsaleem A, Chiang GPK, et al.
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist. Pediatr Rheumatol Online J
2019;17(1):31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6595671</ArticleId>
            <ArticleId IdType="pubmed">31242923</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
